Trastuzumab rezetecan significantly improves progression-free survival in HER2-positive breast cancer, outperforming standard treatments in a pivotal trial.
The phase 3 DREAM3R study randomized patients 2:1 to receive durvalumab 1500 mg every 3 weeks plus chemotherapy every 3 weeks for 4 to 6 cycles, followed by durvalumab maintenance 1500 mg every 4 ...
Adding apalutamide (Erleada) to androgen deprivation therapy (ADT) in patients with biochemically recurrent prostate cancer reduced the risk of developing metastases and castration-resistant disease, ...
212Pb-DOTAMTATE showed significant antitumor activity in PRRT-exposed GEP-NETs, with a 34.6% objective response rate and 96.2% disease control rate. The 18-month progression-free survival and overall ...
Gedatolisib combined with fulvestrant, with or without palbociclib, significantly improved PFS in HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer. The triplet regimen reduced ...
“DESTINY-Breast11 results support T-DXd [plus] THP as a more effective and less toxic neoadjuvant treatment compared with ddAC-THP, and it may become the preferred regimen for patients with high-risk, ...
The combination of pembrolizumab (Keytruda) and lenvatinib (Lenvima) elicited promising progression-free survival (PFS) outcomes in patients with uveal melanoma who were both HLA-A*02:01–negative and ...
Sacituzumab tirumotecan (sac-TMT) significantly improved progression-free survival compared to chemotherapy in HR-positive, HER2-negative breast cancer patients. Sacituzumab tirumotecan significantly ...
Tiragolumab plus atezolizumab did not improve progression-free survival compared to durvalumab in stage III NSCLC patients post-cCRT. Median progression-free survival and overall survival were similar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback